(Q39149515)

English

A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.

scientific article published on 21 May 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Erik Wennerberg

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Pádraig D'arcy

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Andreas Lundqvist

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Deepthy Gurajada

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Stig Linder

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

21 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

62

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1359-1368

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23689729%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Adoptive T cell therapy for cancer in the clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

CTLs respond with activation and granule secretion when serving as targets for T-cell recognition

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Granzymes, a family of serine proteases released from granules of cytolytic T lymphocytes upon T cell receptor stimulation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Inhibition of proteasome deubiquitinating activity as a new cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Activated T cells inhibit NK cell-mediated tumour rejection

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

The clinical trail of TRAIL.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1439-1

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39149515&oldid=2244048634"